MedTrace Logo

Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia

NCT00611806 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2014-08-19

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effectiveness of folate and B12 supplementation in reducing negative symptoms in people with schizophrenia.

Conditions

Interventions

DIETARY_SUPPLEMENT

Folic Acid

Folic acid 2mg po daily

DIETARY_SUPPLEMENT

B12

B12 400 micrograms po daily

OTHER

Placebo

1 capsule po daily

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Donald Goff, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-08-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00611806 on ClinicalTrials.gov